PMC:7253235 / 14059-14374 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"489","span":{"begin":14,"end":22},"obj":"Species"},{"id":"491","span":{"begin":62,"end":77},"obj":"Gene"},{"id":"493","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"494","span":{"begin":134,"end":149},"obj":"Chemical"},{"id":"495","span":{"begin":157,"end":171},"obj":"Chemical"},{"id":"500","span":{"begin":184,"end":198},"obj":"Disease"},{"id":"501","span":{"begin":214,"end":241},"obj":"Disease"}],"attributes":[{"id":"A489","pred":"tao:has_database_id","subj":"489","obj":"Tax:9606"},{"id":"A491","pred":"tao:has_database_id","subj":"491","obj":"Gene:7294"},{"id":"A493","pred":"tao:has_database_id","subj":"493","obj":"MESH:C545373"},{"id":"A495","pred":"tao:has_database_id","subj":"495","obj":"MESH:D005472"},{"id":"A500","pred":"tao:has_database_id","subj":"500","obj":"MESH:D066126"},{"id":"A501","pred":"tao:has_database_id","subj":"501","obj":"MESH:D003329"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T23","span":{"begin":62,"end":70},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma82768"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T148","span":{"begin":223,"end":231},"obj":"Disease"}],"attributes":[{"id":"A148","pred":"mondo_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/MONDO_0005053"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T85","span":{"begin":308,"end":310},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T14","span":{"begin":62,"end":88},"obj":"Chemical"},{"id":"T15","span":{"begin":62,"end":70},"obj":"Chemical"},{"id":"T16","span":{"begin":78,"end":88},"obj":"Chemical"},{"id":"T17","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"T18","span":{"begin":157,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_38637"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_18186"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_78543"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_46345"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T6","span":{"begin":71,"end":88},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T85","span":{"begin":232,"end":241},"obj":"Phenotype"}],"attributes":[{"id":"A85","pred":"hp_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/HP_0025637"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T87","span":{"begin":0,"end":315},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}

{"project":"2_test","denotations":[{"id":"32462289-27022039-24380942","span":{"begin":308,"end":310},"obj":"27022039"},{"id":"32462289-29977352-24380942","span":{"begin":308,"end":310},"obj":"29977352"},{"id":"32462289-31875699-24380942","span":{"begin":308,"end":310},"obj":"31875699"}],"text":"However, some patients receiving other agents such as certain tyrosine kinase inhibitors with prothrombotic risk (i.e., ponatinib) or fluoropyridines (i.e., 5-fluorouracil) may suffer cardiotoxicity in the form of coronary ischemia/vasospasm, which may warrant more invasive diagnostic/treatment strategies [35–37]."}